NASDAQ · ATRC

AtriCure, Inc.

Healthcare · Medical - Instruments & Supplies

$59.12▲ 3.47% ($1.98)at close

As of 4:00 PM ET

52-week

$25.36$59.59

Market cap

$3.01B

P/E

What the market price implies · Reverse DCF

To support a price of $59.12, this model requires revenue to grow by 48.87%/yr over the next 10 years, compounded annually.

Historical revenue grew by 18.15%/yr over the past 4 years. The required annual growth rate is 30.73 percentage points higher.

Selected forecast · Base scenario

10.1%/yr · actual 10-year annualized revenue growth

Year 1 growth: 15.84%

Market-implied · Base operating assumptions + edited margins

48.87%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$59.12

Estimated value / share

$6.55

Base scenario

This estimate is 88.92% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 15.84% · Ending margin 5.52% · Discount rate 11.85%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 4:11 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 58.9%Revenue (TTM): 13.94%FCF (TTM): 601.27%P/S: 53rd pct

What changed

The stock rose 58.9% over the last year. Revenue grew 13.94% over the trailing twelve months. Operating margin moved from -6.82% to 2.44%. Free cash flow grew 601.27% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum, and the shares are still only around the 53rd percentile of their historical P/S range.

What would invalidate this read

Operating margin is at 2.44%. Revenue grew 13.94% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Return analysis

Company profile

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves.

CEOMichael H. Carrel

SectorHealthcare

IndustryMedical - Instruments & Supplies

Employees1,350

IPO dateAug 5, 2005

https://www.atricure.com

Market multiples

Forward P/E—

EV/EBITDA111.39

Enterprise value$1.81B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth12.83%

Gross margin (FY2025)74.41%▼0.3ppvs FY2024

Operating margin (FY2025)-0.64%▲8.0ppvs FY2024

ROE2.15%▲4.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$57.29▼3.10%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est $0.01 · Revenue est $151.18M

View